AP NEWS

Company Profile for VenatoRx Pharmaceuticals, Inc.

January 15, 2019

--(BUSINESS WIRE)--Jan 15, 2019--VenatoRx Pharmaceuticals is a world leader in antibacterial and antiviral drug research and development. VenatoRx’s lead product, VNRX-5133, is an injectable beta-lactamase inhibitor (BLI) that features uniquely potent and selective activity against both serine- and metallo-beta-lactamases. VenatoRx is currently developing VNRX-5133 in a fixed combination with the fourth generation cephalosporin, cefepime. VenatoRx believes that cefepime/VNRX-5133 has the potential to provide a best-in-class broad-spectrum treatment option for infections due to carbapenem resistant pathogens infections including carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA), bioterror pathogens such as Burkholderia spp. and Salmonella spp. engineerable with serine- and metallo-beta-lactamases, and suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents. VenatoRx has been recognized with funding awards from the National Institute of Allergy and Infectious Diseases (NIAID), Wellcome Trust, CARB-X, and the Defense Threat Reduction Agency (DTRA) as well as private equity investments from Versant Ventures, Abingworth and Foresite Capital.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190115005413/en/

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS INFECTIOUS DISEASES PHARMACEUTICAL RESEARCH OTHER SCIENCE SCIENCE

SOURCE: VenatoRx Pharmaceuticals, Inc.

Copyright Business Wire 2019.

PUB: 01/15/2019 10:00 AM/DISC: 01/15/2019 10:01 AM

http://www.businesswire.com/news/home/20190115005413/en

AP RADIO
Update hourly